Almost 12 percent of Americans have used GLP-1 drugs, according to RAND, with injectables including Novo Nordisk's Ozempic and WeGovy and Eli Lilly's Zepbound
The medication's long half-life and gradual mechanism of action mean that a minor adjustment of 24 hours does not typically result in dangerous medication levels or sudden changes in blood glucose control
The Institutes mission is to drive foundational, collaborative, risk-taking research that addresses societys most pressing challenges, including cancer, Alzheimer's disease, and agricultural vulnerability
What research does show: Greater average weight reduction at higher doses Greater HbA1c reduction at higher doses Increased side effects with dose escalation What research does not yet establish: Whether ultra-low doses maintain meaningful long-term weight reduction Whether microdosing produces comparable metabolic outcomes Whether indefinite low-dose therapy is effective for maintenance Much of the online discussion is anecdotal rather than trial-based
Any statements about GLP-1 friendliness must be based on nutritional evidence, not positioned as a guaranteed way to lose weight
